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FAKTOR-FAKTOR YANG MENENTUKAN KELEWATAN DIAGNOSIS 
PENYAKIT TB DAN KESANNYA KE ATAS TRANSMISI PENYAKIT DI 
YEMEN   
 
ABSTRAK 
Tuberkulosis (TB) masih kekal sebagai punca utama kematian dan tahap kesihatan 
yang lemah dengan anggaran 8.8 juta kes baru dilaporkan di seluruh dunia. Kadar 
kes TB seluruh dunia semakin meningkat pada kira-kira 1.1% setiap tahun dan 
bilangan kes pada 2.4% setiap tahun. Kelambatan dalam mendapatkan rawatan TB 
telah meningkatkan lagi transmisi tuberkulosis pulmonari (paru-paru), dan beban 
penderitaan menanggung penyakit ini masih dirasakan di negara-negara sedang 
membangun. Kelewatan dalam mengesan TB juga boleh membawa kepada kadar 
kematian yang semakin meningkat. Walaubagaimanapun, pengesanan awal dan 
rawatan serta-merta adalah penting dalam pencegahan dan kawalan TB yang 
berkesan. Tujuan kajian ini ialah untuk menilai kelewatan dalam pengesanan TB dan 
kesannya ke atas jangkitan TB, sebagai tambahan kepada kesannya ke atas kos pra-
diagnosis.  Kajian telah dijalankan dalam 3 fasa di sebuah pusat rujukan tuberkulosis 
di bandar Sana’a, Yemen. Fasa Pertama menjurus kepada pengenalpastian umum 
tentang masalah kelewatan dan faktor-faktor yang berkaitan. Fasa Kedua bertujuan 
membuat penilaian ke atas kesan kelewatan ke atas jangkitan TB di kalangan 
keluarga atau rakan-rakan rapat. Dalam Fasa Ketiga, hubungan di antara kos pra-
diagnosis dan kelewatan diagnosis ke atas pesakit-pesakit TB telah dinilai. Kira-kira 
505 pesakit TB dengan lumuran positif yang baru telah dilatih untuk kajian ini.  
Kesemua 505 orang pesakit telah diminta menjawab soal kajiselidik dan temuramah. 
Seterusnya, 266 rakan dan keluarga terdekat telah menjalani Ujian Penyaringan 
Tuberkulin (TST). Alat TST ini telah digunakan dalam fasa kedua kajian ini.   
XXIV 
 
Keputusan-keputusan yang diperolehi dalam Fasa Pertama menunjukkan bahawa, 
kelewatan median adalah berjumlah 60 hari, 30 hari untuk kelewatan pesakit dan 10 
hari untuk kelewatan penjagaan kesihatan. Faktor risiko bebas untuk jumlah 
kelewatan yang panjang ialah jantina lelaki, sudah berusia (> 60 tahun), mempunyai 
status pekerjaan, mula mendapatkan rawatan awal di farmasi, rawatan yang tidak 
betul, iaitu dengan antibiotik, bilangan lawatan ke unit penjagaan kesihatan dan  
cauterization sebagai rawatan tradisional.  Untuk kelewatan pesakit yang panjang (> 
30 hari) faktor ialah usia tua (> 60 tahun), rawatan yang tidak betul dengan 
antibiotik, Farmasi sebagai tempat pertama dilawati oleh pesakit-pesakit TB, status 
ekonomi, kesukaran mendapatkan kenderaan pengangkutan dan kelapangan suami. 
Untuk kelewatan penjagaan kesihatan yang lama (> 10 hari) faktor-faktornya ialah 
rawatan yang tidak betul dengan antibiotik, bilangan lawatan ke unit penjagaan 
kesihatan dan aras rendah TB bacilli dalam lumuran pesakit TB.  Dalam Fasa Kedua, 
kelainan dalam pola transmisi TB di kalangan orang terdekat tidak dapat diperolehi.  
Dalam Fasa Ketiga, perbezaan kos pra-diagnosis dapat direkodkan. Perubatan secara 
langsung (kos perubatan, ujian makmal dan ujian Sinar-X Dada) dan faktor bukan-
perubatan secara langsung (kos makanan, pengangkutan dan tempat tinggal) yag 
ditanggung oleh pesakit-pesakit TB adalah berbeza (P < 0.001). Telah dapat 
disimpulkan bahawa faktor-faktor berkaitan pesakit dan sistem penjagaan kesihatan 
telah menyumbang secara signifikan kepada kelewatan dalam diagnosis atau 
pengesanan TB. Lelaki, usia yang tua (> 60 tahun), status pekerjaan, mendapatkan 
rawatan di farmasi, rawatan yang tidak sempurna dengan antibiotik, bilangan lawatan 
ke unit penjagaan kesihatan dan cauterization adalah faktor-faktor risiko untuk 
kedua-dua pesakit dan sistem penjagaan kesihatan, sementara status ekonomi dan  
kesukaran mendapatkan pengangkutan hanyalah faktor-faktor risiko kelewatan 
XXV 
 
pesakit, dan aras tinggi TB bacilli adalah faktor risiko kepada kelewatan sistem 
penjagaan kesihatan. Perbezaan dari sudut transmisi TB di kalangan orang terdekat 
kepada pesakit yang lewat atau tidak terlewat dikesan tidak dikaji.  Pesakit-pesakit 
yang lambat dikesan terpaksa membayar kos tambahan sebelum pengesanan sebenar 
TB dilakukan.  Meningkatkan pengajaran dan kesedaran tentang TB di kalangan 
rakyat dan sistem penjagaan kesihatan telah dicadangkan dalam kajian ini.   
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FACTORS DETERMINING THE DELAY OF TB DIAGNOSIS AND ITS 
EFFECT ON THE DISEASE TRANSMISSION IN YEMEN 
 
   
ABSTRACT 
 
Tuberculosis (TB) still remains a leading cause of mortality and morbidity with an 
estimation of 8.8 million new cases in the world. The global incidence rate of TB 
was growing at approximately 1.1% per year and the number of cases at 2.4% per 
year.  Delay in seeking care of TB increase transmission of pulmonary tuberculosis 
as well as the burden of TB, which remains high in developing countries. This delay 
in the diagnosis of TB also could result in increased patient morbidity and mortality. 
However, early diagnosis and immediate initiation of treatment are essential for an 
effective TB prevention and control. The aim of this study was to evaluate the delay 
in TB diagnosis and its effect on TB transmission in addition to its effect on pre-
diagnosis cost. The study was carried out in 3 phases in a referral centre of 
tuberculosis at Sana’a city, Yemen. Phase One was concerned of a general 
identification of delay problem and its associated factors. Phase Two was aimed to 
assess the effect of delay on TB transmission among close contacts. In Phase Three, 
the relation between pre-diagnosis cost and delay diagnosis of TB patients was 
assessed. About 505 new smears positive TB patients were recruited to this study. 
All of the 505 were subjected to interview questionnaire. Moreover, 266 close 
contacts were subjected to Tuberculin Screening Test (TST). This TST tool was used 
in phase two of this study. The results obtained in Phase One revealed that, median 
delay was 60 days for total, 30 days for patient and 10 days for health care delay. 
Independent risk factors for long total delay were male gender, old age (> 60 years), 
employment status, seeking care at Pharmacy as first place visited by TB patients, 
XXVII 
 
improper treatment with antibiotics, number of visit to health care unit and 
cauterization as traditional treatment. For long patient delay (> 30 days) these were 
old age (> 60 years), improper treatment with antibiotics, Pharmacy as first place 
visited by TB patients, economic status, transportation difficulties and availability of 
husband. For long health care delay (> 10 days) these were improper treatment with 
antibiotics, number of visit to health care unit and low level of TB bacilli in smears 
of TB patient.  In Phase Two, the difference in TB transmission pattern among those 
close contacts could not obtain.  In Phase Three, pre-diagnosis cost differences were 
obtained. Direct medical (medication cost, laboratory investigation and Chest X-Ray 
test,) and direct non-medical (food, transportation and accommodation) costs that 
incurred by TB patients were different (P < 0.001).  It was concluded that patient and 
health care system related factors contribute significantly to delays in the diagnosis 
of TB patients. males gender, old age (> 60 years), employment status, seeking care 
at Pharmacy, improper treatment with antibiotics, number of visit to health care unit 
and cauterization were risk factors of both patient and health care system while 
economic status and Transportation difficulties were only risk factors of patient delay 
and high level of TB Bacilli was risk factor of health care system delay. The 
difference in terms of TB transmission among close contacts of delay and non delay 
patients was not observed. Delayed diagnosis patients were incurred extra costs prior 
to actual TB diagnosis. Promoting knowledge and awareness of TB among both 
population and health care system in public and private sector was recommended.   
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CHAPTER ONE 
INTRODUCTION 
  
1.1 Tuberculosis as a worldwide problem 
Tuberculosis (TB) is one of the most profound health problems worldwide.   
With the recent resurgence of TB and multidrug resistant cases, TB control, which 
depends on rapid identification of TB infection as well as case finding and effective 
treatment, is threatened. Therefore, TB remains as one of the complicated problems 
faced by the world today. It is a chronic communicable continues resistant disease 
caused by microorganism known as Mycobacterium tuberculosis (Yilmaze et al., 
2004; Schwartzman, 2002).   
Tuberculosis is as old as mankind and the history of this disorder is intertwined 
inevitably with the history of civilization. It is also thought to be the oldest of human 
diseases. Many people think of TB as a disease of the past. But, TB is still a leading 
killer of young adults (productive age group) worldwide. Some 2 billion people      
(one-third of the world's population) are infected with the TB bacterium, 
Mycobacterium tuberculosis (CDC, 2008; Jenkins, 1995). It is a disease which is 
spread through the air and usually infects the lungs although other organs are 
sometimes involved. This includes the lemphnodes, bones, kidnys, abdomen, genito-
urinary tract, skin, joints and brain (Anderson and Muirs, 1985; Lucaya and Strife, 
2002). Pulmonary tuberculosis usually occurs in the apex of the lung. This develops 
cavities containing large numbers of tubercle bacilli, which can be detected in 
sputum specimen (Janic, 2003). 
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 Most people who are infected with Mycobacterium tuberculosis harbour the 
bacterium without symptoms while others develop active TB disease. Each year, 8 
million people worldwide develop active TB with 3 million deaths (Paul et al., 
2000). 
   TB is a global emergency. Data obtained from the World Bank reveals that 
TB kills more adults than any other single infectious agent. Additionally, TB 
prevention and control interventions are among the most cost-effective public health 
measures (Ramachandaran and Paramasivan, 2003). Despite the magnitude of the TB 
control strategies, the disease still remains a major public health challenge especially 
in the developing world. Socio-economic problems are considered as complicated 
challenges of patient’s easy access to TB diagnosis and treatment. Conducting of 
well national prevalence survey could assist in understanding such challenges as well 
as in combating TB threatens (Omoleke, 2012). 
 
1.2   Epidemiology of TB 
Tuberculosis continues to be a very major problem throughout the world. A 
more reasonable estimate of the total number of new cases each year is 5.5 million, 
of which 74% occur in Asia and another 12% in Africa (International Union Against 
Tuberculosis and Lung Diseases, IUATLD, 2000). About 95% of deaths due to TB 
are in the developing countries (Sajjad et al., 2003). While the incidence of 
tuberculosis has declined considerably in industrialized countries, the disease still 
poses a serious and even increasing problem in many low-income countries, 
affecting the health and social welfare of millions of people. Fighting tuberculosis is 
a challenge to all who are concerned about health and development (Loddenkemper 
et al., 2002). 
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The trend in case notification (Thomas et al., 2003) suggests that the global 
incidence of tuberculosis is growing, although slowly, i.e. 0.4 % cases/ year (Health 
Protection Agency, 2003). Much more rapid growth of the disease incidence is found 
in sub-Saharan Africa which is linked to the spread of HIV. The rapid growth of 
incidence is also found in countries of the former Soviet Union due to the 
deterioration of public health and public health services (WHO. 2005a). Meanwhile, 
the incidence of tuberculosis continues to decline in western and central Europe and 
in other industrialized countries, and more slowly in Latin America and the Middle 
East (WHO. 2005a).     
According to WHO report (2011), the TB incidence rate was falling or stable 
in all six WHO regions (the Americas, Eastern Mediterranean, Europe, South-East 
Asia, Western Pacific and Africa, Table 1.1). The falling incidence’s rate was by 
1.3% per year since 2002. 
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Table 1.1: Estimated TB incidence, prevalence and mortality of 2010. 
WHO region 
Incidence1 Prevalence 2 Mortality 
No. in 
thousands 
% of 
global 
total 
No. in 
thousands 
No. in 
thousands 
Rate per 
100 000 
pop3 
Africa 2300 26% 2800 250 30 
The Americas 270 3% 330 20 2.2 
Eastern 
Mediterranean 650 7% 1000 95 16 
Europe 
 
420 5% 560 61 6.8 
South-East Asia 3500 39% 5000 500 27 
Western Pacific 1700 20% 2500 130 7.5 
Global total 8800 100% 12000 1100 15 
1 Incidence is the number of new cases arising during a defined period.  
2 Prevalence is the number of cases (new and previously occurring) that exists at a 
given point in time.  
3 Population 
 
The highest number of death was in the South East Asia Region while the 
highest mortality per capita was in the African Region. The decline in the incidence 
rate per capita was offset by population growth. Thus, the number of new cases 
arising each year is still increasing globally in Africa, the eastern Mediterranean and 
South East Asia (WHO, 2011). 
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1.3 Microbiology of TB 
Tuberculosis affects everyone from infants to elderly age. Tuberculosis can 
spread through droplet infection or contaminated foods, such as milk from herds 
infected with Mycobacterium bovis (National Collaborating Centre for Chronic 
Conditions, 2006). Bovine tuberculosis has been almost completely eliminated 
following the pasteurization of milk and the control of infected cattle. Unfortunately, 
there is a reservoir in wild species and it is known to have infected buffaloes and re-
infection of domestic cattle is thus always possible (Spalmer et al., 2002).  
Tuberculosis originally spread from animal to humans, just as AIDS did in 
the twentieth century. It probably leaped from cows to humans about 8,000 or 10,000 
years ago, when people first settled down in communities to tend to their cattle and 
plant their crops. From their cows, some farmers and their families probably 
contracted an airborne infection from Mycobacterium bovis. Sick cows exhaled the 
bacteria, and human beings breathed them in. They may also have got the 
tuberculosis bacteria from the cows’ milk. The bacteria learned to live in the human 
body, which is not that different from a cow, preferring to settle in the lungs, 
although they could attack many other organs (Reichman, 2002). 
The infectious agent of TB (M. tuberculosis) is a thin, slightly curved bacillus 
that is an obligate aerobe. In comparison to other bacteria, M tuberculosis has a cell 
wall with very high lipid content (Kathleen and Arther, 2002; Leung, 1999) that 
resists staining by the usual Gram method.  The unique character of   mycobacteria is 
its acid fastness property (Bruce et al., 1999). Once stained by an aniline dye such as 
carbol fuchsin, it resists decolourisation with acid and alcohol and thus is termed as 
acid and alcohol-fast bacilli (AAFB). This was then shortened to ‘acid fast bacilli’ or 
AFB (Jenkins, 1995; Palomino et al., 2007). 
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Mycobacterium tuberculosis also considered as a non-spore forming, non-motile and 
non-encapsulated bacillus.  
   Acid fastness is related to the uniquely thick cell wall, which is composed of 
an interlacing layer of lipids, peptidoglycans and arabinomannas. The aniline dye 
forms a complex with this layer and is held fast despite the action of the acid-alcohol. 
This allows the detection of AFB in the specimen, with a simple staining technique 
called the Ziel-Neelson (ZN) stain, which has been in use for over 60 years (Monica, 
2000). 
 
1.4 Pathogeneses of TB 
 Inhaling cough droplets or dust particles containing tubercle bacilli can 
causes infection with Mycobacterium tuberculosis. These bacilli can be lodged in the 
lung to form a small inflammatory lesion (WHO, 2004). The bacilli also infect 
adjacent lymph nodes (Monica, 2000). Activated macrophages form a granuloma 
around the site of primary infection, which usually are response (macrophage) to the 
microbial antigen. The immune system cells (mononuclear cells) are recruited to the 
site of the infection. Then the T immune cells produce cytokines, which act on the 
macrophage containing the bacilli at the centre of the granuloma, and control the 
infection. Spread of infection is prevented by confining the bacilli inside the 
granuloma (Gerd-Rudiger and Antonio, 2003).  
The T cells with the activated macrophage work together to isolate and 
inhibit the replication of the bacilli inside the granuloma. Then, the immune cells 
produce toxic substance to inhibit and destroy the bacilli inside granuloma (Monica, 
2000; Palomino et al., 2007). In most patients the primary lesion is self-healing 
although not all the bacilli may be destroyed and some bacilli remain dormant in 
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lymph nodes and may reactivate causing post-primary disease. There may be fibrous 
scarring and sometimes calcification of the healed area. Unfortunately, some bacilli 
may still survive inside granuloma and may reactivate to cause re-infection years 
later (Yancey, 2001).  
Tuberculosis has two general status: latent infection and active disease 
(WHO, 2004). Only those who develop active tuberculosis can transmit the disease. 
The difference between latent tuberculosis and active pulmonary tuberculosis is that 
the presence of symptoms, presence of tubercle bacilli inside sputum sample and the 
abnormal chest X- ray result are usually found within the active TB case. Latent 
infection refers to the remainder of the bacilli inside the body without any 
reactivation (Marilyn, 2001; Schwartzman, 2002). The mycobacterium with active 
tuberculosis (infectious status) will be transmitted from the infected person to 
another depending on several factors which include: 
· The infectiousness of the person with infectious tuberculosis, which is 
related to the number of bacteria that he or she expels and possibly the 
virulence of the bacteria. 
· The length of exposure to an infectious person or to air contaminated with 
tuberculosis bacteria (long time exposure leads to probability of disease 
risk). 
· The environment surrounding an infectious person, for example, the size of a 
room and how well the ventilation is inside the room.  
· The functioning of an exposed person’s immune system (status of immunity 
of the exposed person).  
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1.5 High-risk groups  
The following groups are the high exposure groups to tuberculosis infection, 
(CDC, 2001; American Lung Association, 2011):  
1 - Close contact of persons known as tuberculosis- infected persons or persons 
suspected of having TB (e.g. family and friends).  
2 - Persons infected with HIV. 
3 - Persons who inject drugs or other locally identified high–risk substance users (e.g. 
crack cocaine users).  
4 - Persons who have medical risk factors known to increase the risk for disease if 
infection occurs (diabetes, asthma, immunosuppressive people).   
5 - Residents and employees of high-risk congregate settings (e.g., correctional 
institutions, nursing homes, mental institutions, other long-term residential facilities, 
and shelters for the homeless).  
6 - Health-care workers, who serve high-risk clients.  
7 - Foreign-born persons, including children, recently arrived (within 5 years) from 
countries that have a high TB incidence or prevalence. 
8 - Some medically underserved persons (poor medical service) and low-income 
populations. 
9 - High-risk racial (some races are at more risk of contracting tuberculosis) or ethnic 
minority populations, as defined locally; and infants, children and adolescents 
exposed to adults in high-risk categories.  
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1.6 Tuberculosis transmission 
The source of TB infection (droplet nuclei) is carried to the surrounding 
environment by the air from the infected cases (Jacques, 2003). In this way, the 
disease is spread from person to person. Mycobacterium tuberculosis is contained in 
small particles (droplets) range from 1 to 5 µm in diameter. The droplet nuclei are 
produced when persons with pulmonary tuberculosis cough, sneeze or speak 
(Lawrence, 2000; Rhee, 2001). The droplets may also be produced by aerosol 
treatments, sputum induction, and aerosolization during a bronchoscope and through 
manipulation of lesions or processing of tissue or secretions in the hospital or 
laboratory (Robert et al., 2000). Droplet nuclei contain two to three Mycobacterium 
tuberculosis organisms. The organisms are so small that air currents normally present 
in any indoor space can keep them airborne for long periods of time. The droplet 
nuclei are small enough to reach the alveoli within the lungs, where the organisms 
replicate (Reichman and Hershfield, 2000; Golub, 2002). Although patients with 
tuberculosis can generate larger particles containing numerous bacilli, these particles 
do not serve as effective vehicles for transmission of infection because they do not 
remain airborne. These particles also do not reach the alveoli (if inhaled). Organisms 
deposited on intact mucosa or skin does not invade tissue. When large particles are 
inhaled, they impact on the wall of the upper airways where they are trapped in the 
mucous blanket, carried to the oropharynx, and swallowed or expectorated (Respire, 
2000).  
The transmission of TB can be limited if the disease is diagnosed in a timely 
manner (Yilmaz et al., 2004). The delay in diagnosis of TB can lead to increase 
morbidity and mortality beside persistence of the patients as a reservoir of disease 
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transmission. Delay in the diagnosis may have serious implication at both the 
individual and the community level (Olumuyiwa and Joseph, 2004). 
 
1.6.1 Tuberculin test and TB transmission  
Epidemiologically, Tuberculin Skin Test (TST) is used to investigate the 
transmission of TB among contact (ALA, 2011).The interpretation of the result 
would indicate if the contact is infected or not. TST positive result will indicate that 
the contact is infected with TB. This infected contact with TB may reactivate to 
become a TB patient any time (CDC, 2008). 
In a population with high prevalence of TB, Tuberculin test is more reliable 
due to the high specificity and high sensitivity level of the test in terms of detecting 
the disease (American Thoracic Society, 1999).   
Contact investigations for patients with TB are initiated to identify secondary 
infections and cases. This is because; TB patient with delay diagnosis will give a 
greater chance for TB to transmit to contact (Golub, 2002). The rationale for 
conducting contact investigation is based on two key principles of TB control: 1) to 
treat all cases of disease and 2) to reduce the overall rate of the disease (Rhee, 2001).    
Recently, molecular epidemiology is involved in the assessment of disease 
transmission pattern among contacts. In a practical application of the techniques of 
molecular biology, genetic fingerprinting has been used in epidemiological 
investigation of tuberculosis transmission (Kulaga, 2004). The (IS6110) restriction 
fragment length polymorphism (RFLP) typing is used for tracing the spread of 
Mycobacterium tuberculosis strain. This type has been widely used to demonstrate 
transmission of TB in institutional outbreaks (Diaz et al., 2001). 
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RFLP-typing is one of many typing techniques that are available in which 
polymorphisms in the number or location of repetitive DNA elements (insertion 
sequences) within the bacterial genome can be used in epidemiologic study. An 
insertion element is a piece of DNA that is able to move independently and to insert 
in multiple location in plasmids or chromosomal locations. Copies of this insertion 
sequence (IS) are identical in sequence but their number and location in the genome 
vary. Person-to-person transmission is inferred on the basis of identical or very 
similar DNA fingerprints of the bacterial organism (Kulaga, 2004). 
 
1.7 Diagnosis of TB 
 The diagnosis of TB usually depends on laboratory investigation methods, 
radiographic chest-X rays and the clinical symptoms of the patients (Palomino, 
2007). 
 
 1.7.1 Diagnosis of pulmonary TB   
          The lungs are primarily infected with Mycobacterium tuberculosis. 
Pulmonary TB (PTB) develops in the minority of people whose immune systems do 
not successfully contain the primary infection. The disease may occur within weeks 
after the primary infection, or it may lie dormant for years before causing the disease 
(Darrell, 2002). 
PTB is the common form of tuberculosis in adults. This form (PTB) is the 
only form of tuberculosis which can be infectious and thus has a great 
epidemiological significance (WHO, 2004). 
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1.7.1.(a) Signs and symptoms  
 The symptoms which suggest pulmonary tuberculosis include: 
· Cough persisting for more than three weeks. 
· Loss of weight and loss of appetite. 
· Fever. 
· Dyspnoea (shortness of breath), night sweats, chest pain and hoarseness of 
voice, all of which are uncommon. 
 Patients with the above symptoms should be screened for tuberculosis (WHO, 
2001a). Signs can be subtle especially in minimal cases, or may be obvious including 
those of consolidation, fibrosis or stony dullness caused by pleural effusion. 
 
1.7.1.(b) Investigations 
Diagnosis of suspected TB patients is usually performed via the TB laboratory 
investigations, performing chest-x ray in addition to sign and symptoms of TB that 
are confirmed by TB doctors and specialists.   
 
1.7.1.(b).(i) Laboratory investigation 
Laboratory tests should be used to improve the outcome for individual 
patients or to provide public health information. However, if the quality of laboratory 
tests is poor, resources will be wasted on repeat tests or inappropriate management 
and the laboratory service will be inefficient (Mundy et al., 2003). 
 
 Sputum smear microscopy - Acid fast staining 
For the diagnosis of tuberculosis, the sputum smear microscopy has 
traditionally been the first diagnostic test used to screen for active PTB disease. The 
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smear is usually stained using the acid fast staining method (Michael et al., 2001). 
The acid-fast smear can be performed quickly and can provide information to the 
clinician in less than 24 hours. However, it has several limitations. These limitations 
include the difference of examiners competency in terms of conducting of the AFB 
test, the way of collecting the sputum samples by patients and preparing the samples 
by the technicians (Josephine et al., 1998). 
 For sputum smear microscopy, three specimens of sputum are required 
preferably including one early morning specimen (Peter, 2000). 
 
Culture test 
 
 Culture of the organism can be performed on a conventional egg-based media 
such as Lowenstein-Jensen medium or Middle Brook 7H10 medium. Growth on 
these conventional media takes 4-8 weeks to obtain results (Ganguly et al., 2002a). 
However, radiometric culture method such as the BACTEC method can provide 
results within 2 weeks. This method can be used when there is a need for early 
diagnosis and in smear-negative cases. This method depends on C14 labeled palmitic 
acid which can be utilized by the Mycobacteria, and the radioactive carbon dioxide 
released will be an indicator for the presence of the bacilli (Monica, 2000). 
Sensitivity tests using radiometric method which yield equally rapid results can be 
performed in situations where drug resistance is suspected and urgent results are 
required (MOH, Malaysia, 2002). 
 
Polymerase chain reaction (PCR) technique 
 This method depends on the nucleic acid amplification technique. The PCR 
allows sequences of DNA present in a few copies of mycobacteria to be amplified in 
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vitro, which can be visualized and identified (Padmavathy et al., 2005; CDC, 2008). 
Although PCR technique can give rapid result, it is expensive. False positive reaction 
may result from cross-contamination (MOH, Malaysia, 2000). The false negative 
results may also come from the presence of inhibitor or lack of target gene sequences 
in the causative strain. It must be remembered that PCR can also give a positive 
result in patients who are already on anti-tuberculosis treatment but who are 
excreting small numbers of non-viable bacilli. Thus, this test cannot be used for 
follow-up on patients whose are under treatment (Joseph, 2000). 
 
Serological test  
 Most of the serological tests for diagnosis of TB have high negative 
predictive value or low sensitivity to identify the disease and thus are useful as 
screening tests. Numerous serological tests that use various antigens, such as secreted 
and heat shock protein lipopolysaccharides and peptides have been developed (Sudha 
et al., 2000). Serological tests for tuberculosis should be studied in various 
operational situations before they are widely applied. The limitation of these tests is 
the low sensitivity especially with smear negative patients and also with HIV 
positive cases. Additionally, another difficulties relating to the distinguishing 
between M. tuberculosis and non-tuberculosis mycobacteria were due to the 
similarity of the content of these TB bacilli organisms (Gunguly et al., 2002). 
 
1.7.1.(b).(ii) Mantoux or tuberculin test 
 This test (Tuberculin) is reliable for the diagnosis of tuberculosis in the 
asymptomatic individual (Michael, 2001). It is an extract of the tubercle bacilli, 
which aids in identifying TB infection (Sudha, 1999; CDC, 2008). Tuberculin is 
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administered intra-dermally with 5-tuberculin units. The positive results appear as 
induration around the injection (more than 10 mm in diameter). The result can be 
read within the time frame of 48-72 hours (William, 2001).   
 Tuberculin test has a role in the diagnosis of tuberculosis especially in 
pediatric cases and cases of extra pulmonary tuberculosis.  The Mantoux test is 
carried out in government hospitals in Malaysia using two tuberculin units (T.U) in 
0.1 ml prepared solution (buffer solution). Diameter of indurations of less than 10 
mm is graded as negative. When the reading result is 10 mm or more ( in a child or 
adult) it should be considered as a positive result. The diameter of 15 millimeter or 
more in children is considered as significant for TB and may indicate recent 
infection. A positive Mantoux test merely indicates tuberculosis infection and not 
necessarily active disease. (MOH, Malaysia, 2002; CDC, 2008). 
 The tuberculin test can represent a true infection in the population who are 
only infected with Mycobacterium tuberculosis and also those who are not 
vaccinated with BCG. When people infected with other mycobacteria species are 
subjected to tuberculin test, the false positive result will appear as a cross-reaction 
among them. This cross-reaction (false positive result) occurs due to the reaction 
between the antibodies of TB with similar antigens of mycobacteria rather than M. 
tuberculosis antigen.  
 
1.7.1.(b).(iii) Chest X- ray 
The classic description of the chest radiograph of adults with TB is that of 
“post primary” TB, with nodular or alveolar infiltrates in the upper lung zones (the 
apical and posterior segments of the upper lobes and the superior segment of the 
lower lobes) and evidence of cavitation. This is still a common mode of presentation 
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and, if present, the physician should be prompted to consider the diagnosis. 
Surprisingly, several studies have shown that up to one-third of patients with this 
classic chest radiographic findings are not initially suspected of having TB due to 
many other lung diseases that may mimic the existence of pulmonary TB (Richard 
and Robert, 1999). 
The lesion of TB is revealed in the apical and posterior segments of the upper 
lobes. Lesions are often soft in active pulmonary tuberculosis and there is usually 
little or no fibrosis or calcification. These findings would suggest healed 
tuberculosis. Cavities suggest the diagnosis of active disease unless the patient has 
been previously treated. Apart from the typical sites at the apices, other sites such as 
the apical segment of the lower lobes may also be involved (MOH, Malaysia, 2002). 
  Asnake and Feleke (2000) reported that the radiological diagnosis of TB is 
unreliable, since many other lung diseases may mimic the existence of pulmonary 
TB. In addition, the cost of radiographic examination is high and very often not 
affordable for all cases of TB in low-income countries (WHO, 2005b).   
 
1.7.2 Diagnosis of extra Pulmonary TB (EPTB) 
 
 Tuberculosis of organs other than the lungs is called extra pulmonary 
tuberculosis. EPTB includes the pleura (TB pleurisy), peripheral lymph nodes, 
abdomen, genito-urinary tract, skin, joints, bones, and the brain (National 
Collaborating Centre for Chronic Conditions, 2006). 
Diagnosis of EPTB is often difficult. A negative smear of acid-fast bacilli and 
failure to culture the bacilli contributed to the difficulty of EPTB diagnosis 
(Marjoriep, 2005). Thus, the recognition and understanding of the radiographic 
findings in the EPTB case can reduce the difficulty of EPTB diagnosis (Engin et al., 
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2002). In the post AIDS era (Marco et al, 1998) in USA, 1008 patients with extra 
pulmonary tuberculosis were older than 65 years old. Two thirds of the 4 million 
infected people with both HIV and TB were diagnosed as having extra pulmonary 
tuberculosis. The diagnosis of EPTB tuberculosis is often difficult compared with 
pulmonary TB due to the low sensitivity of the usual diagnostic methods for the 
disease (AFB smear, Mantoux, culture and chest radiography tests). The sensitivity 
of the previous mentioned methods ranges from 25% - 39% (Marco et al., 1998). 
          
 1.7.3 Lymphadenitis TB 
 
Tuberculous lymphadenitis is the most common type of extra pulmonary 
tuberculosis (CDC, 2008). It can be diagnosed by fine needle aspiration (FNA) of 
glands (lymph nodes glands). This type of specimen is accessible especially in the 
neck. The specimen is submitted for AFB test and culture and cytological 
examination. The biopsy specimens may be needed in case of negative FNA test 
results (Sharma and Mohan, 2004). 
 
1.7.4 Pleural effusion TB 
  In certain parts of the world, tuberculosis remains as the most frequent cause 
of pleural effusion in the absence of an obvious pulmonary lesion. Diagnosis of 
tuberculosis in pleural effusion can be made by pleural effusion culture. The biopsy 
can also be used as a specimen to diagnose TB. When the microscopic examination 
of the biopsy specimen is combined with the culture, the diagnosis can be made in 
90% of patients, especially with the use of multiple biopsies (Wilfredo et al., 2000; 
WHO, 2004). 
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1.7.5 Skeletal TB 
 Skeletal tuberculosis typically involves the vertebrae as well as the weight-
bearing bones and joints. The early diagnosis for the disease is critical to the 
preservation of the cartilage and joint space. The diagnosis is performed by a 
radiographic test. The lesion can be evaluated well by CT scanning or magnetic 
resonance imaging (MRI). Unfortunately, these methods are not made available for 
all tuberculosis patients. The tissue biopsy test should also be required especially 
with tuberculosis in the intestine and peritoneum (Sharma and Mohan, 2004; 
Palomino et al., 2007). 
 
1.7.6 Genito-urinary TB 
 The genito-urinary tract is the second most common site for tuberculous 
infection after the lungs as reported by Khan and Chandramohan (2011). According 
to Chattopadhyaya et al., 1997, it has been reported to account for 20% to 70 % of all 
cases of extrapulmonary tuberculosis. The infection almost always affects the 
kidneys during the primary exposure to infection but is not presented clinically 
(Chattopadhyaya et al., 1997). Here the diagnosis of tuberculosis can be made with 
collection of three to six consecutive morning clean urine specimens for culture; 
Radiological investigation can also be made in this case (Wilfredo et al., 2000). 
 
1.7.7 Miliary TB 
 Miliary TB may occur in an individual organ (very rare, < 5%). It also occurs 
in several organs of the body or throughout the whole body (> 90%), including the 
brain. The infection is characterized by the presence of a large amount of TB bacilli. 
Despite the presence of the large amount of bacilli the disease may be misdiagnosed. 
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Up to 25% of patients with miliary TB may have meningeal infection. In addition, 
miliary TB may mimic many diseases. In some case series, up to 50% of cases are 
undiagnosed antemortem (Klaus and De Luise, 2011). Therefore, the high index of 
clinical suspicion is important to obtain an early diagnosis and ensure improved 
clinical outcomes. The diagnosis of this type of tuberculosis can be supported by 
chest X-rays. The liver biopsy, cerebrospinal fluid test required especially in 
tuberculous meningitis and CT scans in brain tuberculosis may also help to assess 
suspected TB lesions (National Collaborating Centre for Chronic Conditions, 2006). 
 
1.8 Drug resistance Mycobacterium 
When streptomycin was discovered in 1943 and introduced as the first 
antibiotic for the treatment of TB, the majority of those treated improved 
dramatically. In most cases, this improvement was followed by a relapse due to 
streptomycin-resistant strains, and the importance of drug resistance in the treatment 
of TB became apparent. It is now known that the use of streptomycin monotherapy 
has led to the emergence of resistant strains. Since drug resistance develops rapidly, 
inadequate treatment or non-adherence to treatment commonly leads to the 
development of drug-resistant disease with subsequent transmission of drug-resistant 
strains within the community (CDC, 2008; Loddenkemper, 2002). 
Primary resistance is the resistance pattern seen in new patients who have not 
been exposed to anti-TB drugs previously. Secondary resistance is the resistance 
pattern in patients with previous history of anti-TB treatment and ineffective 
chemotherapy (Heidarnejad and Nagili, 2001). 
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1.9 Treatment of TB 
   Early diagnosis and prompt treatment of TB is important in order to minimize 
complications and the consequences of the disease. To cure the individual patient of 
tuberculosis, and to minimize the transmission of Mycobacterium tuberculosis to 
other persons are the main two goals of TB treatment. Thus, successful treatment of 
TB has benefits for both the individual patient and the community in which the 
patient resides. For this reason, the prescribing physician, be he/she in the public or 
private sector, is carrying out a public health function with a responsibility of not 
only for prescribing an appropriate drug regimen but also for successful completion 
of therapy. However, given a clear understanding of roles and responsibilities, 
oversight of treatment may be shared between a public health programme and a 
private physician (American Thoraces Society, 2003). 
 Before the discovery of streptomycin, fresh air, plenty of food, sunshine and 
bed rest were the available treatment for TB. Effective chemotherapy was started 
when streptomycin(SM) was discovered in the 1940s. The resistance for this 
treatment was developed, and then it was found that combined chemotherapy with 
streptomycin plus paraaminosalicylic acid (PAS) prevented the emergence of strains 
resistant to streptomycin (Cynamon, 2000). The response to streptomycin plus PAS 
treatment was better than the response of single drug TB treatment. The introduction 
of isoniazide (INH) alone or in combination with SM or PAS in the treatment of 
pulmonary tuberculosis further confirmed the inadequacy of mono therapy due to the 
onset of drug resistance. The standard regimen of chemotherapy contained SM plus 
PAS and had to be given for a minimum of 18 months to 2 years. PAS could be 
substituted by ethambutol (ETH) according to the TB patient acceptability and 
availability (Chan, 1995; Palomino et al., 2007). 
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 Rifampicin, one of the important drugs in the treatment of TB was able to 
kill the very slowly dividing bacteria, the so-called "persisters" in a way that the 
other drugs could not. It was found that by combining this drug with at least two 
others initially, the length of treatment could be reduced to just six months. As 
aresult, the new standard of treatment of tuberculosis became isoniazide (INH), 
rifampicin (R), and pyrazinamide (Z) for two months followed by isoniazide and 
rifampicin for four months (Peter, 1999). 
Shortening the course of anti-tuberculosis treatment to ensure that a person 
completes treatment has been a major practical tuberculosis control research issue for 
decades. Highly efficacious regimens now exist that can be completed in just 6 
months with as few as 62 doses of anti-tuberculosis drugs (James, 2000). The 
shortest course regimen required initiation of treatment with four drugs, including 
isoniazide, rifampicin, and pyrazinamide with either ethambutol or streptomycin as 
the fourth drug (CDC, 2011). The same regimen that makes short-course treatment a 
possibility also covers the potential for single- or even two-drug resistance. Thus, the 
best tuberculosis control strategy for the 1990s dictates initiation of four anti-
tuberculosis drugs in nearly all cases (James, 2000). 
 
1.9.1 Treatment regimens 
     The current recommended TB treatment regimens of the National 
Tuberculosis Programme (NTP) in each country depends on the particular country’s 
budget, health coverage by Public Health Centre (PHC) services and qualifications of 
health staff at peripheral levels (CDC, 2011). For each patient, the regimen 
recommended depends on the patient treatment category (WHO, 2004). The 
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treatment programme of TB based on WHO treatment categories is divided into three 
categories as follows (MOH, Malaysia, 2002): 
· New tuberculosis cases. 
· Relapse, treatment failure, and treatment after interruption. 
· Chronic cases. 
Treatment regimen in each category is divided into two phases, namely 
A) Intensive phase.  
B) Continuation phase. 
In the intensive phase, three or four drugs are given daily while two or three 
drugs are usually given in the continuation phase. In the case of multi-drug resistance 
patients, trained physicians should do the treatment due to the different treatment 
time and regimen (long course of anti TB drugs) compared with patients who are 
infected for the first time. In such cases, it is advisable to manage the patient as an in-
patient until sputum conversion (changing of sputum results from positive to 
negative) is achieved (CDC, 2008; WHO, 2005c). In the management of multi-drug 
resistant TB, the initial regimen should consist of at least three drugs, preferably four 
or five, to which the bacilli are likely to be sensitive. When sputum converts to 
negative, one or more drugs may be withdrawn, preferably a weaker drug which 
causes side effects. The treatment with the weaker regimen should be continued for 
at least 18 months after sputum conversion to prevent relapse (Palomino et al., 
2007). 
 
1.10 DOTS and TB treatment  
 Directly Observed Treatment, Short course (DOTS) is an international 
recommended approach to control TB. It is an inexpensive strategy to prevent 
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millions of TB cases and deaths over the coming decade. The DOT programme is 
involved in providing the anti-tuberculosis drugs directly to the patient and watching 
as he/she swallows the medications. It is the preferred core management strategy for 
all patients with tuberculosis (American Thoracic Society, 2003). Directly Observed 
Treatment Short Course (DOTS) is a comprehensive strategy endorsed by the World 
Health Organization (WHO) and International Union Against Tuberculosis and Lung 
Diseases (IUATLD) to detect and cure TB patients. This strategy of DOTS combines 
five components (WHO, 1999): 
1. Government commitment. 
2. Case detection by sputum smears microscopy. 
3. Standardized treatment regimen. 
4. Regular drug supply. 
5. Standardized recording and reporting system. 
According to WHO report (2005b), the total number of countries 
implementing DOTS were increased by two fold during 2003, bringing the total to 
182 out of 211 countries around the world. There were 22 countries named as high 
burden TB countries and they represent 80% of the global burden of tuberculosis. All 
the 22 High Burden Countries (HBCs) that included in the WHO report have had 
DOTS programmes since 2000; many of these programmes have been established for 
much longer. DOTS as programme to control TB has coverage in all countries 
around the world and its implementation, has been steadily increasing since 1995 
(Amdekar, 2005). 
 
   
24 
 
1.11 Delay in TB diagnosis  
Delays in the diagnosis of tuberculosis (TB) are problems associated with 
many TB patients around the world; these delays may result in increased patient 
morbidity and increased of TB transmission (Mathur et al., 2001). These delays may 
reflect patient delays in seeking care, health care provider (HCP) delays in making 
the diagnosis and starting treatment, or even both patient and HCP delays (Mathur et 
al., 1994; Xu et al., 2006). TB patients are characterized according to the time of 
diagnosis either with short or long diagnostic delay period (Yimer et al., 2005), in 
which the latter period could lead to continuous TB transmission. 
Several studies have sought to establish whether the delay in diagnosis of TB 
is due to a patient delay in seeking care  or due to the inability of the provider (health 
care provider) to diagnose promptly (WHO, 2001b). The literature generally makes a 
distinction between the two normally, patients delay and health care system delay. 
The total delay is the main term of TB delay diagnosis and it consisted of the two 
previous mentioned parts of delay (patient and health care system delay) in addition 
to treatment delay (WHO, 2006a; Zerbini et al., 2008). 
According to WHO, 2006a, and other literatures such as Zerbini et al., 2008; Nguyen 
et al., 2009, the definitions of these types of delay: 
· Patient delay is defined as the time interval between the onset of TB 
symptoms and first consultation at a health care unit.  
· Health care system delay is usually referred to the time between the first visit 
to the health care unit and actual diagnosis of TB (Nguyen et al., 2009). 
· Treatment delay is the time interval between actual diagnoses and starting 
treatment of TB (Zerbini et al., 2008). 
